A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD),
Role: Investigator,
NGM Biopharmaceuticals, Inc.,
(10/2022 - 10/2023)
Status: Completed
A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of Brolucizumab 6 mg compared to Aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(08/2022 - 08/2023)
Status: Completed
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema,
Role: Investigator,
Unity Biotechnology, Inc.,
(06/2022 - 06/2023)
Status: Completed
A 12-Month, 2-Arm, randomized, double-masked, multicenter Phase III study assessing the efficacy and safety of Brolucizumab every 4 weeks versus Aflibercept every weeks in adult patients with visual impairment due to Diabetic Macular Edema (KINGFISHER),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(09/2020 - 09/2021)
Status: Completed
A Phase 2b multicenter dose-ranging study evaluating the safety and efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) compared to Intravitreal Aflibercept in subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO study),
Role: Investigator,
Graybug Vision, Inc.,
(09/2020 - 08/2021)
Status: Completed
Internal
Collection of vitreous and aqueous samples from patient undergoing vitrectomy and intravitreal injections,
Role: Investigator,
LLU Dept. of Ophthalmology,
(03/2020)
Status: Approved